Pharmaceutical

Launching pharmaceuticals in the Nordics: Opportunities...

The Nordics are a well-known powerhouse of pharmaceutical innovation and product...

New 2023 guidelines for the management of cardiomyopathies

A new set of European Society of Cardiology (ESC) guidelines was shared at the 2...

VTE risk elevated in Swedish patients hospitalised for ...

In this 2023 study, Sjoland and other researchers found an elevated excess risk ...

invIOs’s cell therapy secures Austrian Government grant...

Up to 45% of the trial costs for the dose-determining Phase 1b trial will be fun...

Cipla to bolster OTC portfolio with acquisition of Acto...

Cipla Medpro South Africa has signed a binding term sheet to acquire Actor Pharm...

UK MHRA approves AbbVie’s migraine prevention drug Aquipta

The UK MHRA has granted marketing authorisation for AbbVie’s Aquipta (atogepant)...

Chinese NMPA approves AstraZeneca’s Calquence for leuka...

The Chinese NMPA approved for AstraZeneca’s Calquence to treat chronic lymphocyt...

Nestlé divests peanut allergy treatment Palforzia to St...

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergene...

STAT+: Lawmakers call on FDA to issue stricter bone gra...

In the latest edition of STAT's Health Tech newsletter: Biofourmis turmoil, Alex...

STAT+: Humana sues Biden administration over Medicare A...

Humana sued the federal government Friday over a rule that claws back overpaymen...

How a ‘weighted lottery’ helped underserved patients ge...

Residents of disadvantaged neighborhoods were far more likely to be allocated a ...

STAT+: FTC settles with Amgen over $28 billion deal for...

The FTC had challenged the deal over concerns the combined company could abuse i...

STAT+: Pharmalittle: How 98 days may cost J&J big bucks...

J&J's Stelara was approved 98 days too early to qualify for an exemption from Me...

Opinion: Why isn’t there any enforcement of the ACA man...

Most states are not in compliance with this ACA requirement.

STAT+: AstraZeneca bets that gene therapy’s workhorse w...

While billions of dollars are invested in new gene-therapy approaches, AstraZene...

STAT+: The curious case of J&J’s Stelara, the unluckies...

When it comes to the Biden administration's selection of 10 drugs subject to pri...